100% autologous tissue regeneration platform

Our proprietary decellularization process separates stromal cells and extracellular matrix (ECM) from a small omental biopsy sample a, A thermo-responsive hydrogel is produced from the ECM. The stromal cells are reprogramed into induced pluripotent stem cells (iPSCs) which are then incorporated into the hydrogel before being differentiated into the desired functional tissue using our patent-pending methodology.

Learn More
Small biopsy of patient's omentum
undergoes a proprietary
decellularization process.
Separating stromal cells and extracellular
matrix (ECM) from which iPSCs and
personalized hydrogel are produced.
The stem cells are differentiated within the gel to the desired tissue
The engineered tissue is re-implemented in the patient

The future of Spinal Cord Injury treatment

Our proprietary hydrogel combined with motor neurons creates functional spinal cord implants that can bridge injured spinal cord tissue. After successful pre-clinical results, a first human clinical trial is scheduled for 2022.


“Imagine a day when your patient’s own cells are grown into any functional tissue implant.”

Asaf Toker – CEO

World’s first
3D-printed heart
using human cells

In 2019, Matricelf licensed the technology that enabled printing the first [functioning] 3D human heart from cells and matrix derived from a human omentum biopsy from Tel Aviv University.

Regenerative tissue
addressing any
medical indication

Matricelf’s novel regenerative medicine platform aims to cure a range of medical conditions including Spinal Cord Injuries (SCI), Age-related Macular Degeneration (AMD), Parkinson’s Disease, Myocardial Infarction et al.

Making headlines in scientific publications

Awards and Recognition

Contact Us

Feel free to drop us a line below!